ImmuPharma PLC (LSE:IMM) the specialist drug discovery and development company, has told DirectorsTalk that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5
We are pleased to present the interim results for the six months ended 30 November 2015. Revenue for the six month period was £225,000 (2014: £229,000) and the loss after
Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today told DirectorsTalk that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in
Allergy Therapeutics plc (LON:AGY) the fully integrated specialty pharmaceutical company specialising in allergy vaccines, research and development director Tim Higgenbottam talks to DirectorsTalk about ATL US dose ranging study, provides
OptiBiotix Health Plc (LON:OPTI) a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes, CEO Stephen O’Hara talks through the 2016 Investor Presentation. Due to popular demand, the
The Times Migrant mayhem has cost us €29 million, Eurotunnel says: Eurotunnel is claiming more than €29 million in compensation from the French and British governments for disruption to its
Panmure Gordon Analyst Dr Mike Mitchell said today “This morning Allergy Therapeutics has announced it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the US. GrassMATAMPL
Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, has told DirectorsTalk it has completed patient enrolment for its Phase IIb dose-finding study, G204, in the
Share Tips, Bids and Rumours Fosun abandons purchase of Israeli insurer Phoenix: Fosun International has abandoned the purchase of an Israeli insurance company, in the first apparent sign that the
Collagen Solutions Plc (LON:COS) is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, regenerative medicine, and in vitro diagnostic products. It aims to
© 2025 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
